Get the Stockscreener App
405.02
0.04%
0.18
After Hours:
405.02
United Therapeutics Corp stock is traded at $405.02, with a volume of 626.35K.
It is up +0.04% in the last 24 hours and up +34.38% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$404.84
Open:
$401.44
24h Volume:
626.35K
Relative Volume:
0.88
Market Cap:
$18.27B
Revenue:
$2.99B
Net Income/Loss:
$1.21B
P/E Ratio:
16.16
EPS:
25.06
Net Cash Flow:
$1.13B
1W Performance:
+1.12%
1M Performance:
+34.38%
6M Performance:
+31.89%
1Y Performance:
+18.74%
1-Day Range:
$399.80
$407.06
1-Week Range:
$388.73
$407.06
52-Week Range:
$266.98
$436.95
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics Corporation $UTHR Stock Holdings Boosted by Advisors Asset Management Inc. - MarketBeat
United Therapeutics (NASDAQ:UTHR) COO Sells $4,520,538.75 in Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) COO Sells $1,961,050.00 in Stock - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 4,560 Shares of Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Sells $280,203.00 in Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 Shares - MarketBeat
Talon Private Wealth LLC Grows Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Major IPF Treatment Breakthrough: United Therapeutics Reveals TETON-2 Trial Results at European Congress - Stock Titan
Cantor Fitzgerald Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock - Defense World
Equities Analysts Issue Forecasts for UTHR FY2026 Earnings - Defense World
Amundi Has $107.64 Million Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation $UTHR Shares Purchased by Federation des caisses Desjardins du Quebec - MarketBeat
3 High-Growth Stocks Poised to Extend Gains Into Year-End - Investing.com
United Therapeutics stock maintains Buy rating at UBS on IPF opportunity By Investing.com - Investing.com South Africa
United Therapeutics stock maintains Buy rating at UBS on IPF opportunity - Investing.com
Empowered Funds LLC Raises Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Axiom Investors LLC DE Sells 8,419 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Dynamic Technology Lab Private Ltd Invests $867,000 in United Therapeutics Corporation $UTHR - MarketBeat
Brokerages Set United Therapeutics Corporation (NASDAQ:UTHR) PT at $429.62 - MarketBeat
Clark Capital Management Group Inc. Has $29.09 Million Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Hancock Whitney Corp Has $2.04 Million Position in United Therapeutics Corporation $UTHR - MarketBeat
Cantor Fitzgerald Raises Price Target for United Therapeutics (U - GuruFocus
United Therapeutics stock price target raised to $525 by Cantor Fitzgerald - Investing.com
United Therapeutics Corporation (NASDAQ:UTHR) Sees Significant Increase in Short Interest - MarketBeat
HC Wainwright Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price - MarketBeat
United Therapeutics Corporation $UTHR Shares Sold by Alliancebernstein L.P. - MarketBeat
United Therapeutics Corporation $UTHR Stake Cut by Nitorum Capital L.P. - MarketBeat
United Therapeutics (UTHR): Evaluating Valuation After Breakthrough IPF Trial Results Drive Analyst Upgrades - simplywall.st
RSI Suggests Rebound May Be Near in United Therapeutics CorporationCEO Change & Reliable Entry Point Trade Alerts - beatles.ru
Parkman Healthcare Partners LLC Decreases Stake in United Therapeutics Corporation $UTHR - MarketBeat
Does United Therapeutics Corporation have declining or rising EPSTrade Entry Report & Stepwise Trade Signal Guides - beatles.ru
United Therapeutics (NASDAQ:UTHR) Trading Down 4.8% Following Insider Selling - MarketBeat
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio? - Benzinga
Palo Alto Investors LP Has $32.44 Million Position in United Therapeutics Corporation $UTHR - MarketBeat
Oppenheimer Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock - Defense World
Is United Therapeutics Corporation a turnaround storyLong Setup & Precise Buy Zone Identification - خودرو بانک
What’s the RSI of United Therapeutics Corporation stockIPO Watch & Proven Capital Preservation Methods - خودرو بانک
United Therapeutics Corporation (NASDAQ:UTHR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
United Therapeutics EVP Mahon sells $4.2m in shares By Investing.com - Investing.com South Africa
United Therapeutics EVP Mahon sells $4.2m in shares - Investing.com India
Oppenheimer Raises Price Target for United Therapeutics (UTHR) t - GuruFocus
Published on: 2025-09-05 01:07:29 - خودرو بانک
Using Bollinger Bands to evaluate United Therapeutics CorporationMarket Performance Summary & Long-Term Capital Growth Strategies - Newser
United Therapeutics stock price target raised to $500 from $400 at H.C. Wainwright - Investing.com India
UTHR: HC Wainwright & Co. Raises Price Target for United Therape - GuruFocus
United Therapeutics stock price target raised to $500 from $400 at H.C. Wainwright By Investing.com - Investing.com South Africa
Is United Therapeutics Corporation meeting your algorithmic filter criteria2025 Market Overview & Fast Moving Trade Plans - Newser
United Therapeutics Corporation $UTHR Shares Purchased by Vident Advisory LLC - MarketBeat
United Therapeutics Corporation’s volatility index tracking explainedJuly 2025 Setups & Entry Point Confirmation Signals - Newser
United Therapeutics stock price target raised to $560 from $415 at UBS - Investing.com Canada
Will United Therapeutics Corporation benefit from rate cutsQuarterly Market Summary & Reliable Price Breakout Alerts - خودرو بانک
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):